Stockreport

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- INmune Bio [Read more]